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Wilson’s disease is an inherited disorder in which defective biliary excretion of copper leads to its accumulation,
particularly in the liver and brain. Mutations in the ATP7B gene on chromosome 13 cause Wilson’s disease. If left
untreated it will cause liver failure, neurological damage, and will be life threatening. It is considered a rare disease
afflicting approximately 1 in 30,000 persons worldwide, although this rate is similar in the different countries some
places show higher incidence rates. Since Costa Rica reports the highest number of cases per population, essential
public health initiatives that promote wellbeing, prevent disease complications, and prolong life among the affected
population have been carried out during the last decades. The most recent lead in this matter is the conformation of
the Costa Rica’s National Alliance for Wilson’s disease whose main objective is to provide practical, operational, timely
and relevant guidance to patients, families, and healthcare professionals in the region for early diagnosis and treatment.
The development and implementation of the National Alliance for Wilson’s disease activities is crucial because it will
reaffirm that early intervention and appropriate treatment, will reduce if not eliminate the burden of Wilson’s disease.
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Wilson’s disease (WD) also named hepatolenticular
degeneration is a rare genetic disorder that causes ex-
cessive copper accumulation in the liver and brain and
is fatal if not detected and treated [1]. The disease was
named after Samuel Alexander Kinnier Wilson, M.D.,
who in 1912 reported pathologic findings of lenticular
degeneration in the brain associated with cirrhosis of the
liver [2]. The epidemiology of WD varies worldwide it is
estimated that the pathology affects approximately 1 in
30,000 people [3] and one in 90–150 individuals carry a
single abnormal Wilson’s disease gene. Countries like
Costa Rica and Japan show the highest prevalence; 1 in 60
per million people; almost doubling world’s reports [4]; as-
pect that has become a health issue. The elevated number
of cases in Costa Rica could be explained because: the high
rates of consanguinity in the country, in which a small* Correspondence: ceciliamonge4@yahoo.com
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century [5] and low migration rates.
Despite the high incidence of WD in Costa Rica cur-
rently the relation between the number of deaths caused
by hepatolenticular degeneration and the mortality by
other liver diseases is not certain. Therefore a group of
pioneers have been working together in the last years
with the objective of studying profusely this disease and
creating specific treatment and diagnosis guidelines for
the region.
Axiom of Wilson’s disease in Costa Rica:
“When approaching liver disease in Costa Rica; in
patients under 30 years of age with chronic liver
disease not secondary to alcohol consumption; the
most likely diagnosis is Wilson’s disease.” Hevia-
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In 1970 Antillón-Salazar M.D. reported the first patient
with WD in Costa Rica, a 17 year old man [6]. Around
the same time, in Canada, Karl Schosinsky a Costa Rican
M.D. contributed in the development of a precise, quan-
titative, enzymatic method for serum ceruloplasmin de-
termination [7]. About thirteen years later Hevia-Urritia
M.D., treated two young female patients (approximately
16 years old) with fulminant hepatic failure on the same
month (Fig. 1), a rare condition at the time also de-
scribed by McCullough et al. [8] In 1989, the incidence
of WD in Costa Rica was reported as 4.9 per 100000 in-
habitants, the highest in the world. Since the determin-
ation varies greatly upon location, Costa Rican regions
with high incidence were identified and located in the
central part of the country, showing close similarity to
colonization cores (Fig. 2).
On 1990, Herra et al., reported that between 1972 and
1989, 150 cases of WD were diagnosed in Costa Rica; of
these 120 were treated at Hospital San Juan de Dios. Seven
patients died of acute liver failure, hemolytic anemia,
encephalopathy, gastrointestinal bleeding or kidney in-
sufficiency [9].
At the same moment, because of the high prevalence
of WD in Costa Rica nationwide-inter-hospital working
groups, consisting of medical microbiologists and pa-
thologists, were established to analyze different diag-
nostic methods of copper metabolism for accuracy and
effectiveness.
Hevia-Urrutia M.D and a group of patients founded in
1989 the Costa Rican Association of Patients with
Wilson’s Disease (A.C.O.P.A.W.) [10]. The goal of this
association is to bring WD patients and their families
together to inform, educate, and discuss valuable informa-
tion regarding medications, health care, research, family
screening, and support. Since its early days, A.C.O.P.A.WFig. 1 Timeline of Wilson’s Disease Events in Costa Rica. WD: Wilson’s disea
ACOPAW: Costa Rican Wilson’s disease Patient Association, CR: Costa Rica, Shas had an annual meeting the first week of October, led
and coordinated entirely by WD patients.
A major achievement was also obtained in 1989, dur-
ing Oscar Arias Sanchez’s government. The Costa Rican
congress declared WD a “National Interest Disease”, this
ensure the adequate treatment (penicillamine, zinc and
trientine) and management of patients by the Costa Rican
Social Security National Health System (CCSS) (Fig. 1).
During 1997 the determination of the specific genetic
mutations for Costa Rican WD patients proved different
from mutations in US patients and most parts of Europe
[11]; however the mutations observed in these patients
(AsnSer 1270) were the same as those found in patients
with WD in Sicily, Italy [12, 13]. Since then, Wilson’s
disease familial genetic mapping has been an important
research line and has identify other genetic mutations
that affect the population as well the most affected
families in the country.
In 2009, the clinical presentation and demographic
characteristics of the Costa Rican pediatric WD patients
were described and showed similar characteristics to that
in children diagnosed in other countries [14].
As worldwide in Costa Rica WD patients with fulminant
hepatic failure are priority for liver transplant, nevertheless
when this is not an option, innovative medical treatment
with prostaglandins, vitamin E and haemoperfusion is ad-
ministered [15]. In Costa Rica this management protocol
has been used in the last 10 years and has shown positive
outcomes in at least four patients (all women under 20
years of age) (Fig. 1).
In 2015 a collaborative alliance that includes gastro-
enterologists, researchers, neurologists, psychologists,
psychiatrists, surgeons, geneticists, as well as other
healthcare providers was created. The main purpose of
this national alliance is to modify the way healthcare is
delivered to WD patients, assuring that all Costa Ricanse, MD: Medical doctor, FWD: fulminant Wilson’s disease,
SNHS: Social Security National Health System
Fig. 2 Incidence of Wilson’s disease in Costa Rica by canton from 1970 to 1989. Data is presented in cases per 100000 inhabitants
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effectively, rapidly and in a homogenous manner. The
National Alliance for WD based at the San Juan de Dios
Hospital includes healthcare professionals from other cen-
ters like the Hospital Mexico (hepatic transplant team)
and the National Children’s Hospital (genetic screening).
In order to achieve its objectives the National Alliance
for WD has establish a network that activates upon new
possible WD diagnoses. Each member of this coalition
has different roles but work in collaboration during the
whole process which starts with diagnosis confirmation.
Once the diagnosis is established members become fully
involve in the family screening, best treatment option
determination and disease management. The members
also determine in conjunction priority research projects
related to WD, and develop educational activities like
workshops, exercise prescription and referral and other
decision-making tools; addressed for healthcare profes-
sionals. These precise and effective mechanisms of inter-
action and communication have shown great results in
approaching and solving urgent cases of WD, particularly
in cases of fulminant hepatic failure.
The National Alliance for WD in Costa Rica aims to
establish a Latin American Wilson’s disease networkthrough the Latin American Hepatology Association
(ALEH). This network will assist in the establishment of
additional national alliances, centers and committees in
other Latin American countries, to collaborate in the
training of diagnostic, management and treatment pro-
tocols, along with providing educational and scientific
support regarding WD.
Currently the National Alliance for WD in Costa Rica
considers the possible establishment of collaboration
with a research group in Pamplona, Spain; that has devel-
oped a successful gene therapy for WD in animal models.
For the future the creation of joint collaborations and pro-
grams with other organizations outside Costa Rica that
perform similar actions as the National Alliance for
Wilson’s Disease are in scope. These institutions in-
clude: Medlineplus [16], National Library of Medicine
Genetics Home Reference [17], NCBI Genes and Disease,
Wilson’s Disease Association (WDA), American Associ-
ation for the Study of Liver Diseases (AASLD), American
Liver Foundation [18], European Society for Liver diseases
(EASL), Canadian Liver Foundation (CLF) [19] and Euro
Wilson Registry [20].
Because of the high prevalence of WD in Costa Rica
current research is being conducted to improve diagnosis,
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the research initiatives include: new variations of D-
penicillamine load tests to achieve earlier diagnosis, the
significance of free copper levels in patients after diag-
nosis and during treatment, the use of medications
such as tetrathiomolibdate in patients with neurological
symptoms [21], long term results and impact of immediate
physiotherapy in patients with neurological symptoms,
programs for early detection of cognitive and psycho-
logical abnormalities during childhood in undiagnosed pa-
tients, WD screen training for school teachers, zinc as a
possible treatment for pregnant patients and medical
management of fulminant hepatitis secondary to WD with
prostaglandins, haemoperfusion and vitamin E.
Symptoms of Wilson’s disease
The liver is the first organ to be affected by the buildup
of copper due to WD; however, patients are often misdiag-
nosed with infectious hepatitis. Excess copper can also
produce psychiatric or neurologic symptoms [22, 23]
which may cause the patient to present tremors, difficulty
walking, talking and swallowing, along with various de-
grees of mental illness. Other signs and symptoms of WD
include fatigue, lack of appetite, abdominal pain, jaundice,
bruising, edema in the lower extremities, ascites and
Kayser-Fleischer rings on ophthalmological examination
[24]. In Costa Rica, the majority of WD patients exhibit
liver disease and in more than 5% the pathology presents
as fulminant hepatic failure. So it is crucial to test patients
for WD if they have unexplained steatosis, liver failure,
cirrhosis, cholestasis, and neurological impairment, specif-
ically because of the high incidence of Wilson’s disease in
the country.
Specific guidelines for diagnosing Wilson’s disease
Early diagnosis and family screening of WD is fundamen-
tal, so treatment can be initiated before liver failure or
neurological damage ensues. The 2001 International
Meeting of Wilson’s disease, held in Leipzig, concluded
that when evaluating a potential WD patient, these funda-
mental diagnostic elements should be included [25, 26]:
 Ceruloplasmin (ferroxidase enzyme) which is normally
lower than 200 mg/L. When ceruloplasmin is low,
deficiency disorders may occur, including neurological
symptoms like Menkes disease [27]. Serum
ceruloplasmin has also been related, since 1975, to the
detection of problems during early gestation [28].
 Serum free copper, which is normally greater than
200 mcg/L.
 Hepatic copper, which is normally greater than
250 mcg/g dry weight.
 The presence of Kayser-Fleischer rings on slit-lamp
examination. However rings may be absent in up to50 % of patients with hepatic WD and most
asymptomatic siblings, but present in other hepatic
diseases such as primary biliary cirrhosis. In contrast,
Kayser-Fleischer rings are present almost invariably in
neurological WD [29] and in neurodegenerative
diseases like Alzheimer’s disease [30].
While often the criteria of the Leipzig score are met
[25], the combination of Kayser-Fleischer rings and a low
serum ceruloplasmin (<0.1 g/L) level can be sufficient to
establish a diagnosis of Wilson’s disease [26].
Nowadays, the genetic diagnosis is also a feasible option,
especially for family screening. The sequence analysis of
ATP7B gene is clinically available to identify the mutations
in the ATP7B gene on chromosome 13. However, the
existence of more than 500 mutants makes the genetic
testing laborious and expensive [31] and in approximately
17 % of clinically confirmed WD cases, no mutation is
identified [32]. Nevertheless significant genotype-phenotype
correlation exists. ATP7B mutations result in absent or to-
tally nonfunctional Wilson ATPase and are associated with
severe hepatic disease [33, 34] (Table 1).
In Costa Rica, after a patient has been diagnosed it is
essential that family members also get tested. The most
successful WD detection and diagnostic method for
family members of patients diagnosed with WD is as
follows:
 Once a patient is identified with WD, their first and
second degree relatives should undergo screening
for WD through ceruloplasmin determination at the
nephrology laboratory, which specializes in
diagnosing copper metabolism abnormalities,
including WD. Test results are available in a timely
manner (less than 7 days).
 If ceruloplasmin level is low or normal-low, the
result is reported to Hevia-Urrutia M.D. team and
the individual will undergo 24-h urinary copper
screening.
 In cases where both tests are abnormal or positive
for WD, further diagnostic procedures such as a
24-h D-penicillamine challenge, liver biopsy, and
genetic testing may take place.Guidelines for treatment of Wilson’s disease
Patients in Costa Rica diagnosed with WD (symptomatic
and asymptomatic) are referred to a tertiary care level
hospital and followed by specialists in gastroenterology
and hepatology. Patients diagnosed with fulminant WD
undergo an inter-hospital protocol for treatment of ful-
minant hepatic failure and liver transplant.
Several drugs are available for the treatment of
Wilson’s disease, including D-penicillamine, trientine,




Kayser-Fleischer Rings Liver Copper (in the absence
of cholestasis)
Present 2 >5x ULN (>4 μmol/g) 2
Absent 0 0.8-4 μmol/g 1
Neurologic Symptomsb Normal (<0.8 μmol/g) -1
Severe 2 Rhodamine -positive granulesa 1
Mild 1 Urinary copper (in absence
of acute hepatitis)
Absent 0 Normal 0
Serum Ceruloplasmin 1-2x ULN 1
Normal (>0.2 g/L) 0 >2x ULN 2
0.1-0.2 g/L 1 Normal but >5x ULN after
D penicilamine
2






Present 1 On 1 chromosome detected 1
Absent 0 No mutations detected 0
TOTAL SCORE EVALUATION




2 or less Diagnosis
very unlikely
Scoring System on Wilson’s disease. 8th International Meeting on Wilson’s
disease. Leipzig, 2001
aIf no quantitative liver copper available, bor typical abnormalities at brain
magnetic resonance imaging. ULN, upper limit of normal
Table 2 Treatment recommendations for Wilson’s disease [26]
• Initial treatment for symptomatic
patients with Wilson’s disease
should include a chelating agent
(D-penicillamine or trientine).
Trientine may be better tolerated
• Patients with acute liver failure
due to Wilson’s disease should be
treated with liver transplantation
when the revised King’s score is
11 or higher
GRADE II-1, B, 1 GRADE II-2, B, 1
AASLD Class I, Level B AASLD Class I, Level B
• Zinc may have a role as a line
therapy in neurological patients
• Patients with decompensated
cirrhosis, unresponsive to chelation
treatment, should be evaluated
promptly for liver transplantation
GRADE II-2, C, 2 GRADE II-2, B, 1
AASLD Class II, Level C AASLD Class I, Level B
• Treatment of presymptomatic
patients or those with neurological
disease on maintenance therapy
can be accomplished with a
chelating agent or with zinc
• Treatment for Wilson’s disease
should be continued during
pregnancy, but dosage reduction
is advisable for D-penicillamine
and trientine
GRADE II-1, B, 1 GRADE II-3, B, 1
AASLD Class I, Level B AASLD Class I, Level C
• Treatment is lifelong and should
not be discontinued, unless liver
transplantation is performed
• For routine monitoring, serum
copper and ceruloplasmin, liver
enzymes and international
normalized ratio, functional
parameters, complete blood count
and urine analysis as well as
physical and neurological
examinations should be performed
regularly, at least twice annually
GRADE II-1, B, 1 GRADE II-2, B, 1
AASLD Class I, Level B AASLD Class I, Level C
• If zinc is used, careful monitoring
of transaminases is needed, with
changing to chelators if these
laboratory parameters are
increasing
• The 24-h urinary copper excretion
on medication and after 2 days
of cessation of therapy should
be measured at least yearly. The
estimated serum non ceruloplasmin
bound copper may be another
useful parameter to control therapy
GRADE C1
AASLD Class I, Level B
• Patients should avoid intake of
foods and water with high
concentrations of copper,
especially during the year of
treatment
GRADE II-3, B, 2 GRADE II-3, B, 1
AASLD Class I, Level C AASLD Class I, Level C
8th International Meeting on Wilson’s disease. Leipzig, 2001
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are designed to remove excess copper and to prevent
its accumulation. If treatment is initiated immediately
after diagnosis, for both presymptomatic and symptomatic
patients, deterioration can be avoided and life expectancy
can be comparable to healthy subjects; of course, a patient
must be compliant with their therapy. In Costa Rica, treat-
ment with zinc during pregnancy and nursing is consid-
ered because of the teratogenic effects of chelating agents
like D-penicillamine and trientine.
Diet is an additional consideration and WD patients
should avoid foods naturally high in copper including:
chocolate, nuts, mushrooms, crustaceans, soy and gel-
atin, along with the use of cooking utensils containing
copper. To ensure the safety of water flowing through
copper pipes, water should run for a few minutes before
drinking [29]. The fact that in Costa Rica rural areas,
from where many WD patients come from, have a high
copper diet constitutes an aspect that must be taken into
account (Table 2).Conclusion
While hepatolenticular degeneration is a rare disease
worldwide, it is much more common in Costa Rica. Im-
portant advances relating the pathology have being made
in the last decades through a series of actions and efforts
in health policy, politics, and multidisciplinary work. One
of the latest interventions is the foundation in 2015 of the
National Alliance for Wilson’s disease.
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for Wilson’s disease is to promote awareness and early
intervention of WD in a country un-proportionally
afflicted with this deadly disease. Currently this initiative
has begun implementing actions by evaluating guidelines
for early diagnosis and adequate treatments, dissemin-
ation of relevant information on current research, legal
issues and the support for WD patients and families;
that have proof substantial reduction on Wilson’s disease
affliction.
The future prospects of the Costa Rican WD National
Alliance is the establishment of international clinical
and research collaborations with other Latin American
countries, Europe and Japan. As well the development
of relations with similar organizations like the Wilson
Disease Centers of Excellence. These mutual benefit
collaborative initiatives are the cornerstone for future
diagnosis, treatment and management of WD.
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